Nestle gets peanut allergy treatment with $2 billion Aimmune buyout

  • 📰 Reuters
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 97%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Nestle to pay $2 billion to purchase the rest of peanut allergy treatment maker Aimmune Therapeutics

), gaining full ownership of the first U.S.-approved peanut allergy treatment which has struggled with a slow launch due to the COVID-19 pandemic.

Shares “started 2020 right about at this level before the pandemic, and resultant shut-down of allergy clinics across the U.S. essentially killed the launch of Palforzia,” Piper Sandler analyst Christopher Raymond said. Peanut allergies are prevalent in an estimated 1.6 million teens and children in the United States alone, making it a lucrative market that could eventually help Aimmune bring in billions of dollars in sales.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Oh, Nestle, the company involved in the Baby Food scandal. The company that used lots of Water in California when it had a drought.

Foreigners should not be allowed to buy US drug makers.

Just so they can sell more peanut butter KitKat's?!

I did miss that.

Tk Later

Et la boucle est bouclée ! Je te nourris, je te rends malade, je te soigne et je gagne des milliards !

'Introducing new Aimmune flavored candies...'

Peanut on both sides of the business. Eat some, get sick - we have the cure.

It should be free.

Unbelievable, they use their industrial food to cause allergies to their customers and then treat them. Double profits!! evil

Nestle? Oh no

and anytime now near or later you will read that Peanut allergy treatment goes up and up in cost.......... its fully commercial now....... and profit baised.......

So?

That's alot of peanuts.

Sounds ominous.

I'm sure they're set to be the biggest FMCG in the world. Whilst under their employ; that was always the mission & vision.

Surprised it’s not Hershey. Even their normal chocolate tastes like peanuts

DAY 101 - LIVE PROTESTS -

👀☠️

they're literally selling the problem to profit with the solution

A A A A A ACACAACCACA ACAcacacacacaccacacacacacacacacacacaa a a a2

As I verify the expiration date on my epi-pen, fuck no! Even if I was not allergic, I hate the smell of peanuts.

Let’s have a lead paint company take ownership of lead treatment too.

Destroy criminal BLM and Antifa

Conflict of interest?

DNA keeps the heathens alive, vampires.

Big Nut (big pharma)

Oh shit... Eat our product that contains nuts, get sick, take our allergy shot, increase profits. Nestle just owning the entire market! Cant wait till this practice starts catching on in healthcare.

Clever move.

Surely there has to be some kind of conflict of interest here?

Oh that doesn’t seem like a conflict or anything. 🙄 Next we will be letting the sugar industry control insulin. Oh wait it looks like Nestle already sells “diabetes pills”. What is this world coming to?

They will continue to harvest billions of $ from such food

They also bottle free water to sell to people.

Creepy as fuck

Classic poison-and-cure gambit. FuckNestle

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Nestle to buy Aimmune Therapeutics for $2.6 billionNestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster to its health science portfolio. About the author of ‘How can we thrive working from home?’ Cherie Diaz is the Managing Director of Australian operations at OpenLearning Limited (ASX:OLL) PwC Australia will on Monday release a report which recommends a tighter partnership between industry and government to address future skills needs with 'micro-credentials'. OpenLearning is leading this Micro Credentials!!
Source: Reuters - 🏆 2. / 97 Read more »

Nestle pays $2 billion to secure Aimmune's allergy treatmentNestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics , as the Swiss company expands its fast-growing health science business. Seeing that Nestle is getting into medical treatment game, does it the mean that Nestle will stop stealing water from Michigan and bottling it for profit? I wouldn't purchase a product made or distributed by Nestle, if they were the only choice available.
Source: Reuters - 🏆 2. / 97 Read more »